Interactions of antiarrhythmic drugs with implantable defibrillator therapy for atrial and ventricular tachyarrhythmias

Current Cardiology Reports

Volumn 1, Issue 4, 1999, Pages 282-288

  Krol, Ryszard B ^a   Saksena, Sanjeev ^a   Prakash, Atul ^a  

^a not available   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIARRHYTHMIC AGENT;

DEFIBRILLATOR; HEART ATRIUM FIBRILLATION; HEART VENTRICLE FIBRILLATION; HEART VENTRICLE TACHYCARDIA; HUMAN; MULTIMODALITY CANCER THERAPY; PATHOPHYSIOLOGY; RECURRENT DISEASE; REVIEW;

ANTI-ARRHYTHMIA AGENTS; ATRIAL FIBRILLATION; COMBINED MODALITY THERAPY; DEFIBRILLATORS, IMPLANTABLE; HUMANS; RECURRENCE; TACHYCARDIA, VENTRICULAR; VENTRICULAR FIBRILLATION;

EID: 0033222901     PISSN: 15233782     EISSN: 15343170     Source Type: Journal    
DOI: 10.1007/s11886-999-0051-7     Document Type: Article

References (96)

1. Echt DS, Liebson PR, Mitchell LB, et al.: Mortality and morbidity in patients receiving encainide, flecainide or placebo. The Cardiac Arrhythmia Suppression Trial. N Engl J Med 1991, 324:781-788.
2. Waldo AL, Camm AJ, deRuyter H, et al., for the SWORD Investigators. Effects of d-sotalol on mortality in patients with left ventricular dysfunction after recent and remote myocardial infarction. Lancet 1996, 348:7-12. (Pubitemid 26237238)
3. Siebels J, Kuck K-H, and the CASH Investigators: Implantable cardioverter defibrillator compared with antiarrhythmic drug treatment in cardiac arrest survivors (the Cardiac Arrest Study Hamburg). Am Heart J 1994, 127(Suppl):1139 1144.
4. Mason JW, for the ESVEM Investigators: A comparison of electrophysiologic testing with Holter monitoring to predict antiarrhythmic-drug efficacy for ventricular tachyarrhythmias. N Engl J Med 1993, 329:445-451. (Pubitemid 23222329)
5. Burkart F, Pfister M, Kiowski W, et al. : Effect of antiarrhythmic therapy on mortality in survivors of myocardial infarction with asymptomatic complex ventricular arrhythmias: Basel Antiarrhythmic Study of Infarct Survival (BASIS). J Am Coll Cardiol 1990, 16:1711-1718.
6. Doval HC, Nul DR, Grancelli HO, et al. , for the Grupo de Estudio de la Sobrevida en la Insuficiencia Cardiaca en Argentina (GESICA): Randomised trial of low-dose amiodarone in severe congestive heart failure. Lancet 1994, 344:493-498. (Pubitemid 24261565)
7. Ceremuzynski L, Kleczar E, Krzeminska-Pakula M, et al. : Effect of amiodarone on mortality after myocardial infarction: A double-blind, placebo-controlled pilot study. J Am Coll Cardiol 1992, 20:1056 1062.
8. Singh SN, Fletcher RD, Fisher SG, et al. , for the Survival Trial of Antiarrhythmic Therapy in Congestive Heart Failure: Amiodarone in patients with congestive heart failure and asymptomatic ventricular arrhythmia. N Engl J Med 1995, 333:77-82.
9. Cairns JA, Connolly SJ, Roberts R, Gent M: Randomised trial of outcome after myocardial infarction in patients with frequent or repetitive ventricular premature depolarisation: CAMIAT. Canadian Amiodarone Myocardial Infarction Arrhythmia Trial Investigators Lancet 1997 349:675-682. (Pubitemid 27107745)
10. Julian DG, Camm AJ, Frangin g, et al.: Randomised trial of effect amiodarone on mortality in patients with left-ventricular dysfunction after recent myocardial infarction: EMIAT. European Myocardial Infarct Amiodarone Trial Investigators. Lancet 1997, 349 667-674. (Pubitemid 27107744)
11. The Antiarrhythmics Versus Implantable Defibrillators (AVID) Investigators: A comparison of antiarrhythmic drug therapy with implantable defibrillators in patients resuscitated from near-fatal ventricular arrhythmias. N Engl J Med 1997, 337:1575-1583.
12. The CASCADE Investigators: Randomized antiarrhythmic drug therapy in survivors of cardiac arrest. [The CASCADE Study] Am J Cardiol 1993, 72:280-287.
13. Bigger JT Jr.: Prophylatic use of implanted cardiac defibrillators in patients at high rigk for ventricular arrhythmias after coronaryartery bypass graft surgery. Coronary Artery Bypass Graft (CABG) Patch Trial Investigators N Engl J Med 1997, 337:1569-1575. (Pubitemid 27509759)
14. Moss AJ, Hall WJ, Cannom DS, et al., and the MADIT Investigators: Improved survival with an implanted defibrillator in patients with coronary artery disease at high risk for ventricular arrhythmia. N Engl J Med 1996 335:1933-1940. (Pubitemid 26428217)
15. Connolly SJ, Gent M, Roberts RS, et al., on behalf of the CIDS Co-Investigators: Canadian Implantable Defibrillator Study (CIDS): Study design and organization. Am J Cardiol 1993, 72:103F-108F. (Pubitemid 23360764)
16. Wever EFD, Hauer RNW, van Capelle FJL, et al. : Randomize study of implantable defibrillator as first-choice therapy versus conventional strategy in post infarct sudden death survivors. Circulation 1995, 91:2195-2203.
17. Larsen GC, McAnult JH, Hallstrom A, et al.: Hospitalization changes in the Antiarrhythmics Versus Implantable Defibrillators (AVID) Trial: the AVID economic analysis stud [abstract]. Circulation 1997 96(Suppl1):1-77.
18. Fogoros RN, Fielder SB, Elson JJ: The automatic implantable cardioverter-defibrillator in drug-refractory ventricular tachyarrhythmias Ann Intern Med 1987, 107:635-641.
19. Kelly PA, Cannom DS, Garan H, et al.: The automatic implantable cardioverter defibrillator: efficacy, complications and survival in patients with malignant ventricular arrhythmias. J Am Coll Cariol 1988, 11:1278-1286.
20. Tchou PJ, Kadri N, Anderson J, et al.: Automatic implantable cardioverter defibrillators and survival of patients with left ventricular dysfunction and malignant ventricular arrhythmias. Ann Intern Med 1988, 109:529 534.
21. Myerburg RJ, Luceri RM, Thurer R, et al.: Time to first shock and clinical outcome in patients receiving an automatic implantable cardioverter-defibrillator. J Am Coll Cardiol 1989, 14:508-514. (Pubitemid 19199779)
22. The PCD Investigator Group: Clinical outcome of patients with malignant ventricular tachyarrhythmias and a multiprogrammable cardioverter-defibrillator implanted with or without thoracotomy: An international multicenter study. J Am Coll Cardiol 1994, 23:1521-1530.
23. Echt DS, Armstrong K, Schmidt P, et al.: Clinical experience, complications, and survival in 70 patients with the automatic implantable cardioverter/ defibrillator. Circulation 1985, 71:289-296. (Pubitemid 15157089)
24. Winkle RA, Mead RH, Ruder MA, et al.: Long-term outcome with the automatic implantable cardioverter-defibrillator. J Am Coll Cardiol 1989, 13:1353-1361. (Pubitemid 19114208)
25. Fromer M, Brachmann J, Block M, et al.: Efficacy of multimodal device therapy for ventricular tachyarrhythmias as delivered by a new implantable pacing cardioverterdefibrillator. Results of a European multicenter study of
26. implants. Circulation 1992, 86:363 374.
27. Bardy GH, Troutman C, Poole JE, et al.: Clinical experienc with a tiered-therapy, multiprogrammable antiarrhythmia device. Circulation 1992, 85:1689-1698.
28. Sperry RE, Stabler BS, Cycan A, et al.: Has antiarrhythmic drug use declined in patients receiving implantable cardioverter defibrillators (ICDs) [abstract]? J Am Coll Cardiol 1993, 21:155A.
29. Olatidoye AG, Aarons D, Juanteguy J, Veltri EP: Clinical outcome of patients with refractory ventricular tachycardia/ fibrillation treated with implantable cardioverter defibrillator and no concomitant antiarrhythmic drug therapy J Am Coll Cardiol 1994, 1A-484A.
30. Lavergne T, Daubert JC, Chauvin M, et al.: Preliminary clinical experience with the first dual chamber pacemaker defibrillator. PACE 1997, 20:182-188. (Pubitemid 27053857)
31. Reiter MJ, Mann DE: Sensing and tachyarrhythmia detection problems in implantable cardioverter defibrillators. J Cardiovasc Electrophysiol 1996, 7:542 558. (Pubitemid 26156425)
32. Huang SK, Tan de Guzman WL, Chenarides JG, et al.: Effects of long-term amiodarone therapy on the defibrillation threshold and the rate of shocks of the implantable cardioverter-defibrillator. Am Heart J 1991, 122:720-727.
33. Kou WH, Kirsh MM, Bollin SF, et al.: Effect of antiarrhythmic drug therapy on the incidence of shocks in patients wh receive an implantable cardioverter defibrillator after a single episode of sustained ventricular tachycardia/fibrillation. PACE 1991, 14:1586-1592.
34. Anderson JL, Karagounis LA, Roskelley M, et al.: Effect of prophylactic antiarrhythmic therapy on time to implantable cardioverter-defibrillator discharge in patients with ventricular tachyarrhythmias. Am J Cardiol 1994, 73:683-687. (Pubitemid 24128859)
35. Pacifico A, Hohnloser SH, Williams JH, et al., for the d,l-Sotalol Implantable Cardioverter-Defibrillator Study Group: Prevention of implantable-defibrillator shocks by treatment with sotalol. N Engl J Med 1999, 340:1855-1862. (Pubitemid 29272665)
36. Ellenbogen K, Luceri R, Dorian P, et al., and Phase I Clinical Investigators: Clinical evaluation of implantable cardioverter defibrillator (CD) function: Importance of data logging to assess device efficacy [abstract]. Circulation 1991, 84(Suppl II):II-426.
37. Dorian P, Fain ES, Davy JM, Winkle RA: Lidocaine causes a reversible concentration-dependent increase in defibrillation energy requirements. J Am Coll Cardiol 1986, 8:327-332. (Pubitemid 16036466)
38. Barold SS, McVernes R, Stokes K: Effects of drugs on pacing threshold in man and canines: old and new facts In New perspectives in cardiac pacing. Edited by Barold SS, Mugica J. Mount Kisco, NY: Futura Publishing; 1993:57-83.
39. Jung W, Manz M, Pizzulli L, et al.: Effects of chronic amiodarone therapy on defibrillation threshold in man. Am J Cardiol 1992, 70:1023-1027.
40. Dorian P, Wong M, David I, Feinedell C: Oral clofilium produces sustained lowering of defibrillation energy requirements in a canine model. Circulation 1991, 83:614-621.
41. Hohnloser SH, Woosley RK: Drug therapy: Sotalol. N Engl J Med 1994, 331:31.
42. Wong M, Dorian P: d-l and d-sotalol decrease defibrillation energy requirements. PACE 1989, 12 1522-1529. (Pubitemid 19221907)
43. Johnson WD, Saedi SF, Kamath ML, et al.: Allopurinol lowers defibrillation thresholds [abstract]. J am Coll Cardiol 1994, 23:85A.
44. Li HG, Thakur RK, Zardini M, et al.: Ethanol increases the defibrillation thresholds in patients with implantabl defibrillators [abstract]. J Am Coll Cardiol 1993, 21:304A.
45. Benser ME, Huang Y, Walcott GA, et al.: Bolus administration of intrapericardial ibutilide: its dynamic effect on myocardial refractory period and defibrillation threshold [abstract]. J Am Coll Cardiol 1998, 31:514A.
46. Qi X-Q, Newman D, Dorian P: Azimilide decreases defibrillation voltage requirements and increases spatial organization during ventricular fibrillation. J Intervent Cardiac Electrophysiol 1999, 3:61-67.
47. Manz M, Jung W, Luderitz B: Interactions between drugs and devices: Experimental and clinical studies. Am Heart J 1994, 127(Suppl):978-984.
48. Senatore C, Coltorti F, Giordano B, et al.: Defibrillation threshold in patients with ICD and concomitant antiarrhythmic drug therapy [abstract]. PACE 1999, 22(II):803.
49. Fisher JD, Kim SG, Matos JA, Ostrow E: Comparative effectiveness of pacing techniques for termination of well-tolerated sustained ventricular tachycardia. PACE 1983, 6:915 920.
50. Naccarelli GV, Zipes DP, Rahilly GT, et al.: Influence of tachycardia cycle lengths and antiarrhythmic drugs on pacing termination and acceleration of ventricular tachycardia. Am Heart J 1983, 105:1-5. (Pubitemid 13223462)
51. Levine JH, Mellits ED, Baumgardner RA: Predictors of first discharge and subsequent survival in patients with automatic implantable cardioverter- defibrillators. Circulation 1991, 84:558-566.
52. Kannel WB, Abbot RD, Savage DD, McNamara PM: Epidemiologic features of chronic atrial fibrillation: the Framingham study. N Eng J Med 1982, 306:1018-1022. (Pubitemid 12155370)
53. Wellens HJJ, Lau C-P, Luderitz B, et al.: Atrioverter: an implantable device for the treatment of atrial fibrillation. Circulation 1998, 98 1651-1656. (Pubitemid 28500388)
54. Bailin SJ, Sulke N, Swerdlow CD, for the Worldwide 7250 Jewel AF-Only Investigators: Clinical experience with a dual chamber implantable cardioverter defibrillator in patients with atrial fibrillation and flutter [abstract]. PACE 1999, 22(II):871.
55. Reuter DG, Kriplen MM, Hoyt RH, et al.: Early recurrence of atrial fibrillation with an implantable atrial defibrillator: incidence, clinical predictors and time course [abstract]. 71st Sci Session :I-191.
56. Wharton M, Santini M: Treatment of spontaneous atrial tachyarrhythmias with the Medtronic 7250 Jewel AF: Worldwide clinical experience [abstract]. 71st Sci Session:I-190.
57. Levy S, Lauribe P, Dolla E, et al.: A randomized comparison of external and internal cardioversion of chronic atrial fibrillation. Circulation 1992, 86:1415 1420.
58. Alt E, Schmitt C, Ammer R, et al.: Initial experience with intracardiac atrial defibrillation in patients with chronic atrial fibrillation. Pacing Clin Electrophysiol 1994, 17:1067 1078. (Pubitemid 24145532)
59. Saksena S, Prakash A, Mongeon L, et al.: Clinical efficacy and safety of atrial defibrillation using biphasic shocks and current nonthoracotomy endocardial lead configurations. Am J Cardiol 1995, 76:913-921.
60. Murgatroyd FD, Slade AKB, Sopher M, et al.: Efficacy and tolerability of transvenous low energy cardioversion of paroxysmal atrial fibrillation in humans. J Am Coll Cardiol 1995, 25:1347-1353.
61. Levy S, Ricard P, Lau CP, et al.: Multicenter low energy transvenous atrial defibrillation (XAD) trial results in different subsets of atrial fibrillation. J Am Coll Cardiol 1997, 29:750-755. (Pubitemid 27128247)
62. Lok N-S, Lau C-P Tse HF, Ayers GM: Clinical shock tolerability and effect of different right atrial electrode locations on efficacy of low energy human transvenous atrial defibrillation using an implantable lead system. J Am Coll Cardiol 1997, 30:1324-1330. (Pubitemid 27501453)
63. Jung J, Heisel A, Fries R, Kollner V: Tolerability of internal lowenergy shock strengths currently needed for endocardial atrial cardioversion. Am J Cardiol 1997, 80:1489 1490. (Pubitemid 27523036)
64. Ammer R, Alt E, Ayers G, Schmitt C , et al.: Pain threshold for low energy intracardiac cardioversion of atrial fibrillation with low or no sedation. PACE 1996, 19:230-236
65. Tomassoni G, Newby KH, Kearney MM, et al.: Testing different biphasic waveforms and capacitances: effect on atrial defibrillation threshold and pain perception J Am Coll Cardiol 1996, 28:695-699.
66. Rossi M, Lown B: The use of quinidine in cardioversion. Am J Cardiol 1967, 19:234 238.
67. Sodermark T, Edhag O, Sjogren A, et al.: Effect of quinidine on maintaining sinus rhythm after conversion of atrial fibrillation or flutter. A multicenter study from Stockholm. Br Heart J 1975, 37:486-492.
68. Van Gelder IC, Crijns HJGM, Van Gilst WH, et al.: Effects of flecainide on the atrial defibrillation threshold. Am J Cardiol 1989, 63 112 114. (Pubitemid 19018952)
69. Prakash A, Edmonds P, Giorgberidze I, Holt P: Pharmacological priming before external DC cardioversion for atrial fibrillation [abstract]. PACE 1996
70. Iskos D, Lurie KG, Adler SW, et al.: Effect of parenteral d-sotalol on transvenous atrial defibrillation threshold in a canine model of atrial defibrillation Am Heart J 1996, 1. 116 119.
71. Bianconi L, Mennuni M, Lukic V, et al.: Effects of oral propafenone administration before electrical cardioversion of chronic atrial fibrillation: a placebo-controlled trial. J Am Coll Cardiol 1996, 28:700-706 (Pubitemid 26288653)
72. Strickberger S, Labhasetwa V, Davis J, et al.: Reduced defibrillation thresholds with endocardial administration of artilide [abstract]. J Am Coll Cardiol 1996, 27:265A.
73. Newby K, Waugh R, Hardee M, et al.: Amiodarone decreases defibrillation threshold in patients undergoing elective cardioversion for atrial defibrillation. Circulation 1996, 94:I-666.
74. Mongeon L, Hill M, Mehra R: Procainamide decreases atrial defibrillation requirements in sustained atrial fibrillation conditioned canines. Circulation 1996, 94:I-136 I-137.
75. Oral H, Souza JJ, Michaud AF, et al.: Facilitating transthoracic cardioversion of atrial fibrillation with ibutilide pretreatment. N Eng J Med 1999, 340:1349-1354.
76. Lai LP, Lin JL, Huang SKS: Sotalol decreases atrial defibrillation energy requirement in humans by increasing atrial refractory period but not by decreasing spatial dispersion of refractoriness: a bi-atrial basket mapping study [abstract]. 71st Sci Session (Suppl I):I-634.
77. Boriani G, Biffi M, Capucci A, et al.: Atrial fibrillation: favorable effects of flecainide in transvenous low energy internal atrial cardioversion [abstract]. J Am Coll Cardiol 1998, 31(Suppl A) 196A.
78. Natale A, Tomassoni G, Beheiry S, et al.: Effect of chronic administration of amiodarone on internal atrial defibrillation [abstract]. 71st Sci Sessions:I-711.
79. Kumagai K, Yamanouchi T, Tashiro N, et al.: Low energy synchronous transcatheter cardioversion of atrial flutter/ fibrillation in the dog. J Am Coll Cardiol 1990, 16:497-501. (Pubitemid 20245877)
80. White JB, Fotuhi PC, Pedoto RW, et al.: reduction in atrial defibrillation threshold by radiofrequency ablation is caused by an increase in fibrillatory wavefront organization [abstract]. PACE 1999, 22(II):725.
81. Ott P, Arentz T, Blum T, et al.: of atrial fibrillation: effect of pre-shock RR interval [abstract]. J Am College Cardiol 1998, 31(Suppl A):332A.
82. Saksena S, Prakash A, Krol RB, Shankar A: Regional endocardial mapping of spontaneous and induced atrial fibrillation in patients with heart disease and refractory atrial fibrillation. Am J Cardiol 1999, in press.
83. Saksena S, Shankar A, Prakash A, Krol RB: Catheter mapping of spontaneous and induced atrial fibrillation in man. J Intervent Cardiac Electrophysiol 1999, 3(Suppl):in press.
84. Giorgberidze I, Saksena S, Mongeon L, et al.: Effects of high frequency atrial pacing in atypical atrial flutter and atrial fibrillation. J Intervent Card Electrophys 1997, 1:111-123. (Pubitemid 127503789)
85. Murgatroyd F, Slade A, Nitzsche R, et al.: A new pacing algorithm for the suppression of atrial fibrillation. PACE 1994, 17 863-867.
86. Reithmann C, Hoffmann E, Spitzlberger G, et al.: Catheter ablation of proarrhythmic atrial flutter due to amiodaron therapy for paroxysmal atrial fibrillation [abstract]. PACE 1999, 22(II):27.
87. Nabar A, Rodriquez LM, Timmermans C, et al.: Radiofrequenc ablation of "class IC atrial flutter" in patients with resistant atrial fibrillation. Am J Cardiol 1999, 83 785-787. (Pubitemid 29115458)
88. Delfaut P, Saksena S, Prakash A, Krol RB: Long-term outcome of patients with drug-refractory atrial flutter and fibrillation after single and dual site right atrial pacing for arrhythmia prevention. J Am Coll Cardiol 1998, 32:1900-1908. (Pubitemid 29010453)
89. Prakash A, Krol RB, Saksena S, Sumar R: Ablation of coexisting atrial flutter elicited using an electrophysiologic strategy in atrial fibrillation improves drug efficacy [abstract]. PACE 1999, 22(II):743.
90. Prakash A, Krol RB, Saksena S, Sumar R: Ablation of coexisting atrial flutter elicited using an electrophysiologic strateg in atrial fibrillation improves drug efficacy in refractor patients. PACE 1999, in press.
91. Saksena S, Prakash A, Hill M, et al.: Prevention of recurrent atrial fibrillation with chronic dual site right atrial pacing. J Am Coll Cardiol 1996, 28 687-694. (Pubitemid 26288651)
92. Huang DT, Monahan KM, Zimetbaum P, et al.: Hybrid pharmacologic and ablative therapy: a novel and effective approach for the management of atrial fibrillation. J Cardiovasc Electrophysiol, 1998:9:462 469.
93. Saksena S, Delfaut P, Prakash A, et al.: How to pace to prevent atrial fibrillation. Proceedings from the International Meeting on Atrial Fibrillation: Evolving Concepts and New Therapeutic Strategies, Bologna, Italy, October 1997.12-14
94. Flaker GC, Blackshear JL, McBride R, et al., on behalf of The Stroke Prevention in Atrial Fibrillation Investigators: Antiarrhythmic drug therapy and cardiac mortality in atrial fibrillation. J Am Coll Cardiol 1992, 20:527-532.
95. Mongeon LR, Warman EN, Mehra R: One right atrial linear lesion decreases atrial defibrillation thresholds in a canine model of sustained atrial fibrillation [abstract]. PACE 1999, 22(II):755.
96. Kalman J, Olgin J, Karch M, et al.: Effect of right atrial linear lesions on atrial defibrillation threshold. Implications for 'hybrid therapy [abstract]. PACE 1996, 19(II):625.